| Literature DB >> 27591863 |
Sabine Baumgartner1, Rouyanne T Ras2, Elke A Trautwein2, Ronald P Mensink3, Jogchum Plat3.
Abstract
PURPOSE: Plant sterols and stanols interfere with intestinal cholesterol absorption, and it has been questioned whether absorption and plasma concentrations of fat-soluble vitamins and carotenoids are also affected. We conducted a meta-analysis to assess the effects of plant sterol and stanol consumption on plasma fat-soluble vitamin and carotenoid concentrations.Entities:
Keywords: Cholesterol; Fat-soluble vitamins; Hydrocarbon carotenoids; Oxygenated carotenoids; Plant stanols; Plant sterols
Mesh:
Substances:
Year: 2016 PMID: 27591863 PMCID: PMC5346416 DOI: 10.1007/s00394-016-1289-7
Source DB: PubMed Journal: Eur J Nutr ISSN: 1436-6207 Impact factor: 5.614
Fig. 1Flowchart study selection process. The literature search retrieves 1084 potentially relevant papers, 1009 are excluded after screening titles and abstracts, 75 articles are reviewed in full and 41 randomized controlled trials (RCTs) are included in the meta-analysis
Effects of plant sterol or plant stanol consumption on plasma carotenoid, fat-soluble vitamin, lipid and lipoprotein concentrations
|
| Unit | Baseline concentrationa | Concentration after PS interventionb | Absolute change versus placebo | Relative change versus placebo | |
|---|---|---|---|---|---|---|
|
| ||||||
| β-Carotene | 53 | µmol/L | 0.60 (0.54; 0.67) | 0.52 (0.46; 0.57) | −0.08 (−0.09; −0.07)1 | −16.3 (−18.3; −14.3)1 |
| 54 | µmol/mmolTC | 0.10 (0.09; 0.11) | 0.09 (0.08; 0.10) | −0.01 (−0.01; −0.01)1 | −10.1 (−12.3; −8.0)1 | |
| α-Carotene | 38 | µmol/L | 0.19 (0.15; 0.24) | 0.18 (0.14; 0.22) | −0.02 (−0.02; −0.01)1 | −14.4 (−17.5; −11.3)1 |
| 37 | µmol/mmolTC | 0.03 (0.03; 0.04) | 0.03 (0.02; 0.04) | 0.00 (0.00; 0.00)1 | −7.8 (−11.3; −4.3)1 | |
| Lycopene | 42 | µmol/L | 0.57 (0.49; 0.65) | 0.54 (0.45; 0.63) | −0.04 (−0.04; −0.03)1 | −12.3 (−14.6; −10.1)1 |
| 41 | µmol/mmolTC | 0.10 (0.08; 0.11) | 0.10 (0.08; 0.11) | 0.00 (−0.01; 0.00)1 | −6.3 (−8.6; −4.0)1 | |
|
| ||||||
| Lutein | 23 | µmol/L | 0.38 (0.31; 0.45) | 0.34 (0.29; 0.40) | −0.02 (−0.03; −0.01)1 | −7.4 (−10.1; −4.8)1 |
| 22 | µmol/mmolTC | 0.06 (0.05; 0.07) | 0.06 (0.05; 0.07) | 0.00 (0.00; 0.00) | −1.5 (−4.6; 1.6) | |
| Zeaxanthin | 13 | nmol/L | 63.90 (52.22; 75.57) | 55.39 (45.13; 65.65) | −7.81 (−11.09; −4.53)1 | −12.9 (−18.9; −6.8)1 |
| 12 | nmol/mmolTC | 10.72 (8.34; 13.09) | 9.78 (7.74; 11.81) | −0.70 (−1.20; −0.21)2 | −7.7 (−13.8; −1.7)3 | |
| β-Cryptoxanthin | 17 | µmol/L | 0.28 (0.22; 0.35) | 0.26 (0.20; 0.32) | −0.03 (−0.04; −0.02)1 | −10.6 (−14.3; −6.9)1 |
| 16 | µmol/mmolTC | 0.05 (0.04; 0.06) | 0.05 (0.04; 0.06) | 0.00 (0.00; 0.00)3 | −4.8 (−8.7; −0.95) | |
|
| ||||||
| α-Tocopherol | 55 | µmol/L | 35.76 (33.63; 37.89) | 33.16 (31.27; 35.06) | −2.43 (−2.81; −2.05)1 | −7.1 (−8.0; −6.2)1 |
| 54 | µmol/mmolTC | 5.91 (5.63; 6.18) | 5.92 (5.63; 6.20) | −0.01 (−0.06; 0.03) | −0.3 (−1.1; 0.5) | |
| γ-Tocopherol | 22 | µmol/L | 3.00 (2.55; 3.46) | 2.91 (2.39; 3.43) | −0.17 (−0.24; −0.11)1 | −6.9 (−9.8; −3.9)1 |
| 21 | µmol/mmolTC | 0.51 (0.42; 0.60) | 0.53 (0.43; 0.64) | 0.00 (−0.01; 0.01) | 0.2 (−3.2; 3.6) | |
| Retinol | 46 | µmol/L | 2.65 (2.14; 3.16) | 2.50 (2.08; 2.91) | −0.02 (−0.04; 0.00) | −0.8 (−1.8; 0.2) |
| Vitamin D | 28 | nmol/L | 57.56 (51.47; 63.65) | 57.95 (51.10; 64.80) | −0.45 (−0.91; 1.81) | 1.4 (−1.7; 4.4) |
|
| ||||||
| TC | 63 | mmol/L | 5.96 (5.80; 6.12) | 5.54 (5.39; 5.69) | −0.39 (−0.42; −0.36)1 | −6.5 (−7.1; −6.0)1 |
| LDL-C | 64 | mmol/L | 3.87 (3.72; 4.01) | 3.50 (3.36; 3.64) | −0.35 (−0.38; −0.32)1 | −9.0 (−9.8; −8.2)1 |
| HDL-C | 62 | mmol/L | 1.44 (1.40; 1.48) | 1.43 (1.38; 1.48) | 0.00 (−0.00; 0.01) | 0.2 (−0.4; 0.7) |
| TAG | 60 | mmol/L | 1.37 (1.30; 1.43) | 1.30 (1.23; 1.37) | −0.06 (−0.08; −0.04)1 | −4.6 (−6.0; −3.2)1 |
Expressed as means (95 % CI)
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, PS plant sterols or plant stanols, TC total cholesterol, TAG triacylglycerol
1 P < 0.0001; 2 P < 0.01; 3 P < 0.05
aFor parallel studies, the weighted average baseline concentrations were calculated based on the baseline concentrations in the active and placebo groups and for crossover studies, the end-of-intervention concentrations of the placebo periods were used
bFor parallel studies, the weighted average concentrations after PS intervention were calculated based on the concentrations after PS intervention in the active groups and for crossover studies, the end-of-intervention concentrations of the active periods were used
Fig. 2Forest plot relative change (expressed as summary estimates and 95 % CIs) in non-standardized (left panel) and TC-standardized (right panel) plasma β-carotene concentrations. The solid squares represent the weight of individual study arms, and the pooled effect estimate is represented as a diamond. Heterogeneity is assessed using Cochran’s Q test (P < 0.1 indicates significant heterogeneity) and quantified by I2, where >50 % indicates substantial heterogeneity
Fig. 3Forest plot relative change (expressed as summary estimates and 95 % CIs) in non-standardized (left panel) and TC-standardized (right panel) plasma lutein concentrations. The solid squares represent the weight of individual study arms, and the pooled effect estimate is represented as a diamond. Heterogeneity is assessed using Cochran’s Q test (P < 0.1 indicates significant heterogeneity) and quantified by I2, where >50 % indicates substantial heterogeneity
Fig. 4Forest plot relative change (expressed as summary estimates and 95 % CIs) in non-standardized (left panel) and TC-standardized (right panel) plasma α-tocopherol concentrations. The solid squares represent the weight of individual study arms, and the pooled effect estimate is represented as a diamond. Heterogeneity is assessed using Cochran’s Q test (P < 0.1 indicates significant heterogeneity) and quantified by I2, where >50 % indicates substantial heterogeneity
Covariate analyses of absolute and relative TC-standardized changes in β-carotene, lutein, α-tocopherol and total cholesterol concentrations after plant sterol or plant stanol consumption
| Covariate | Subgroup definition |
| Change vs. placebo | 95 % CI |
| Change vs. placebo | 95 % CI |
|
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| Baseline | <0.09 µmol/mmoLTC | 27 | −0.007 | (−0.009; −0.005) | 0.059 | −9.8 | (−12.6; −7.0) | 0.747 |
| >0.09 µmol/mmoLTC | 27 | −0.011 | (−0.015; −0.007) | −10.5 | (−13.7; −7.3) | |||
| Dose | 0.45 ≤ dose ≤ 1.6 | 16 | −0.008 | (−0.012; −0.005) | 0.985 | −8.5 | (−12.3; −4.7) | 0.587 |
| 1.6 < dose ≤ 2.0 | 14 | −0.008 | (−0.013; −0.004) | −9.9 | (−14.4; −5.5) | |||
| 2.0 < dose ≤ 3.0 | 16 | −0.007 | (−0.010; −0.005) | −11.2 | (−15.1; −7.3) | |||
| 3.0 < dose ≤ 9.0 | 8 | −0.008 | (−0.014; −0.003) | −13.8 | (−21.2; −6.4) | |||
| Duration | ≤4 weeks | 28 | −0.007 | (−0.009; −0.005) | 0.093 | −8.7 | (−11.2; −6.1) | 0.050 |
| >4 weeks | 26 | −0.010 | (−0.014; −0.007) | −13.2 | (−17.0; −9.5) | |||
| Sterol vs. stanol | Sterol | 31 | −0.007 | (−0.009; −0.005) | 0.206 | −8.9 | (−11.3; −6.5) | 0.039 |
| Stanol | 23 | −0.010 | (−0.014; −0.006) | −14.2 | (−18.6; −9.8) | |||
Expressed as means (95 % CI)
TC total cholesterol
1 P value between subgroups <0.05 indicates a significant difference in pooled effect sizes between subgroups